The use of a Drp1 inhibitor, mdivi-1, has been shown to reduce hypoxia-induced fragmented mitochondrial morphology in PASMCs, decrease endoplasmic reticulum stress, inhibit PASMCs proliferation, and alleviate hypoxia-induced pulmonary hypertension and vascular remodeling (Zhuan et al., 2020; Chen et al., 2018a; Xiao et al., 2022b). The gene discussed is DNM1L; the disease is pulmonary arterial hypertension.